Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

From: Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound.

Advertisements

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Nat. Rev. Cardiol. doi: /nrcardio

The MASS-DAC Study.

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Nat. Rev. Cardiol. doi: /nrcardio

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.

Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

Stenting of Coronary Arteries in Non Stress/Benestent Disease

Nat. Rev. Cardiol. doi: /nrcardio

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Different manifestations of myocardial ischaemia

Glenn N. Levine et al. JACC 2016;68:

Nat. Rev. Cardiol. doi: /nrcardio

Bern-Rotterdam Registry Published in the Lancet

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 1 Anatomy of the femoral artery

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Biosimilar development process

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

P. Foëx British Journal of Anaesthesia

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Peter K. Smith, MD The Annals of Thoracic Surgery

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Manual thrombus aspiration

Figure 1 Milestones in coronary angioplasty

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Observational studies on multiple treatment strategies

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Tornado diagram of one-way deterministic sensitivity analysis.

Figure 1 Ischaemic conditioning

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Platelet receptors and available pharmaceutical options

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

Nat. Rev. Cardiol. doi: /nrcardio

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.12 Figure 1 Timeline of antiplatelet therapy after percutaneous coronary intervention Figure 1 | Timeline of antiplatelet therapy after percutaneous coronary intervention. ARC, Academic Research Consortium; BMS, bare-metal stent; DAPT, dual antiplatelet therapy; FIM, first-in-man; PCI, percutaneous coronary intervention; RCT, randomized clinical trial; SAPT, single antiplatelet therapy; SES, sirolimus-eluting stent. Miyazaki, Y. et al. (2017) Single or dual antiplatelet therapy after PCI Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.12